Serum Antibody against Unfused Recombinant E7 Protein of Human Papillomavirus Type 16 in Cervical Cancer Patients

Takuma Fujii, Youko Matsushima, Masazumi Yajima, Takashi Sugimura, Masaaki Terada

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Sera were examined for the presence of antibody against E7 protein of human papillomavirus type 16 (HPV‐16) by Western blot analysis using the bacterially derived unfused protein. The occurrence rates of anti‐E7 antibody against HPV‐16 were 14.1% (10/71) in cervical cancer patients, 0% (0/48) in cervical intraepithelial neoplasia patients, and 0% (0/41) in female non‐malignant patients. Three patients (one with endometrial cancer, one with breast cancer, and one male patient with colon polyp) out of 115 patients with tumors in organs other than the cervix, had antibody against E7 protein of HPV‐16. The serum antibody, once positive, could be detected for a long time after surgical removal of the cancers in all cases that could be followed up. HPV‐16 DNA could be detected in 50% (13/26) of cervical cancer patients. Sixty‐nine percent (9/13) of patients with HPV‐16 DNA in cancers had the antibody and all the patients with stages II, III, and IV cervical cancer (8/8) harboring HPV‐16 DNA showed the presence of the antibody against E7 protein of HPV‐16. In contrast, only 20% (1/5) of cervical cancer patients with stage Ia or Ib harboring HPV‐16 DNA showed positive for the anti‐E7 antibody in sera. These findings suggest that the presence of anti‐E7 antibody in serum depends on the staging of cervical cancer and extent of HPV infection.

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalJapanese Journal of Cancer Research
Volume86
Issue number1
DOIs
Publication statusPublished - 01-01-1995

Fingerprint

Human papillomavirus 16
Recombinant Proteins
Uterine Cervical Neoplasms
Antibodies
Serum
DNA
Proteins
Male Breast Neoplasms
Neoplasms
Cervical Intraepithelial Neoplasia
Endometrial Neoplasms
Polyps
Cervix Uteri
Colon
Western Blotting

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Fujii, Takuma ; Matsushima, Youko ; Yajima, Masazumi ; Sugimura, Takashi ; Terada, Masaaki. / Serum Antibody against Unfused Recombinant E7 Protein of Human Papillomavirus Type 16 in Cervical Cancer Patients. In: Japanese Journal of Cancer Research. 1995 ; Vol. 86, No. 1. pp. 28-34.
@article{b3c210403a8e45fa9203396c8247f736,
title = "Serum Antibody against Unfused Recombinant E7 Protein of Human Papillomavirus Type 16 in Cervical Cancer Patients",
abstract = "Sera were examined for the presence of antibody against E7 protein of human papillomavirus type 16 (HPV‐16) by Western blot analysis using the bacterially derived unfused protein. The occurrence rates of anti‐E7 antibody against HPV‐16 were 14.1{\%} (10/71) in cervical cancer patients, 0{\%} (0/48) in cervical intraepithelial neoplasia patients, and 0{\%} (0/41) in female non‐malignant patients. Three patients (one with endometrial cancer, one with breast cancer, and one male patient with colon polyp) out of 115 patients with tumors in organs other than the cervix, had antibody against E7 protein of HPV‐16. The serum antibody, once positive, could be detected for a long time after surgical removal of the cancers in all cases that could be followed up. HPV‐16 DNA could be detected in 50{\%} (13/26) of cervical cancer patients. Sixty‐nine percent (9/13) of patients with HPV‐16 DNA in cancers had the antibody and all the patients with stages II, III, and IV cervical cancer (8/8) harboring HPV‐16 DNA showed the presence of the antibody against E7 protein of HPV‐16. In contrast, only 20{\%} (1/5) of cervical cancer patients with stage Ia or Ib harboring HPV‐16 DNA showed positive for the anti‐E7 antibody in sera. These findings suggest that the presence of anti‐E7 antibody in serum depends on the staging of cervical cancer and extent of HPV infection.",
author = "Takuma Fujii and Youko Matsushima and Masazumi Yajima and Takashi Sugimura and Masaaki Terada",
year = "1995",
month = "1",
day = "1",
doi = "10.1111/j.1349-7006.1995.tb02984.x",
language = "English",
volume = "86",
pages = "28--34",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "1",

}

Serum Antibody against Unfused Recombinant E7 Protein of Human Papillomavirus Type 16 in Cervical Cancer Patients. / Fujii, Takuma; Matsushima, Youko; Yajima, Masazumi; Sugimura, Takashi; Terada, Masaaki.

In: Japanese Journal of Cancer Research, Vol. 86, No. 1, 01.01.1995, p. 28-34.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum Antibody against Unfused Recombinant E7 Protein of Human Papillomavirus Type 16 in Cervical Cancer Patients

AU - Fujii, Takuma

AU - Matsushima, Youko

AU - Yajima, Masazumi

AU - Sugimura, Takashi

AU - Terada, Masaaki

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Sera were examined for the presence of antibody against E7 protein of human papillomavirus type 16 (HPV‐16) by Western blot analysis using the bacterially derived unfused protein. The occurrence rates of anti‐E7 antibody against HPV‐16 were 14.1% (10/71) in cervical cancer patients, 0% (0/48) in cervical intraepithelial neoplasia patients, and 0% (0/41) in female non‐malignant patients. Three patients (one with endometrial cancer, one with breast cancer, and one male patient with colon polyp) out of 115 patients with tumors in organs other than the cervix, had antibody against E7 protein of HPV‐16. The serum antibody, once positive, could be detected for a long time after surgical removal of the cancers in all cases that could be followed up. HPV‐16 DNA could be detected in 50% (13/26) of cervical cancer patients. Sixty‐nine percent (9/13) of patients with HPV‐16 DNA in cancers had the antibody and all the patients with stages II, III, and IV cervical cancer (8/8) harboring HPV‐16 DNA showed the presence of the antibody against E7 protein of HPV‐16. In contrast, only 20% (1/5) of cervical cancer patients with stage Ia or Ib harboring HPV‐16 DNA showed positive for the anti‐E7 antibody in sera. These findings suggest that the presence of anti‐E7 antibody in serum depends on the staging of cervical cancer and extent of HPV infection.

AB - Sera were examined for the presence of antibody against E7 protein of human papillomavirus type 16 (HPV‐16) by Western blot analysis using the bacterially derived unfused protein. The occurrence rates of anti‐E7 antibody against HPV‐16 were 14.1% (10/71) in cervical cancer patients, 0% (0/48) in cervical intraepithelial neoplasia patients, and 0% (0/41) in female non‐malignant patients. Three patients (one with endometrial cancer, one with breast cancer, and one male patient with colon polyp) out of 115 patients with tumors in organs other than the cervix, had antibody against E7 protein of HPV‐16. The serum antibody, once positive, could be detected for a long time after surgical removal of the cancers in all cases that could be followed up. HPV‐16 DNA could be detected in 50% (13/26) of cervical cancer patients. Sixty‐nine percent (9/13) of patients with HPV‐16 DNA in cancers had the antibody and all the patients with stages II, III, and IV cervical cancer (8/8) harboring HPV‐16 DNA showed the presence of the antibody against E7 protein of HPV‐16. In contrast, only 20% (1/5) of cervical cancer patients with stage Ia or Ib harboring HPV‐16 DNA showed positive for the anti‐E7 antibody in sera. These findings suggest that the presence of anti‐E7 antibody in serum depends on the staging of cervical cancer and extent of HPV infection.

UR - http://www.scopus.com/inward/record.url?scp=0028843260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028843260&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.1995.tb02984.x

DO - 10.1111/j.1349-7006.1995.tb02984.x

M3 - Article

C2 - 7737906

AN - SCOPUS:0028843260

VL - 86

SP - 28

EP - 34

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 1

ER -